Bioavailability in Supplements: What the Label Means

By Jack Zheng, MS Pharmacy -- Founder of MIHIYO Labs

Summary

Bioavailability in supplements means the fraction of a dose that reaches systemic circulation unchanged, but labels often blur together total exposure, peak level, and speed of absorption. In healthy volunteers, oral caffeine reached essentially complete bioavailability at 108.3%, while oral melatonin was only about 15%, showing why the same word can hide very different pharmacology. Metrics such as AUC, Cmax, and Tmax tell different parts of that story. For MIHIYO Labs, an oral dissolving strip (ODS) only makes sense when route is the real bottleneck, not when bioavailability is being used as marketing decoration.

What does "bioavailability" actually mean on a supplement label?

On a supplement label, bioavailability should mean how much of a dose reaches systemic circulation unchanged. That is the pharmacokinetic definition. The problem is that labels often use the word as a loose promise that a product is stronger, faster, or somehow more advanced, even though those are different questions.¹²

Bioavailability is not a mood word. It is a measurement problem. Kwan described oral bioavailability as the combined result of absorption plus losses in the gut lumen, gut wall, and liver before the surviving fraction reaches systemic blood.¹ Toutain and Bousquet-Melou framed it similarly and emphasized that it can be assessed in absolute or relative terms.²

The next distinction is that not every product using the word has measured absolute bioavailability. Absolute bioavailability compares a non-intravenous dose against an intravenous reference. Most supplements do not have that kind of study package, so many label claims are really shorthand for something narrower: better dissolution, earlier peak levels, or a route that should reduce first-pass loss in theory.² If the data are only relative, the claim should be read as relative.

Which numbers are labels usually hinting at?

If a label says a product is more bioavailable, the useful follow-up question is: more of what, exactly?

Researchers usually separate the concept into total exposure, peak concentration, and timing. Chen, Lesko, and Williams argued that systemic exposure is better described with measures such as total area under the concentration-time curve, early partial AUC when fast onset matters, and peak plasma concentration, rather than by a vague claim that one form is simply "better absorbed."³ In plain language, AUC tells you how much of the dose reached the blood over time, Cmax tells you how high the peak went, and Tmax tells you when that peak arrived.²³

That distinction matters because a route can improve one of those measures without improving all of them. A faster format can shorten Tmax while leaving total exposure roughly unchanged. A stronger peak can raise Cmax without meaning the product is better for every use case. This is why supplement claims that compress all three ideas into one adjective usually tell the buyer too little.

A buyer does not need to become a pharmacokinetic specialist to use these numbers well. If the label is promising more of the dose reaches circulation, look for AUC or absolute bioavailability data. If it is promising a quicker effect, look for Tmax or early AUC data. If it is promising a sharper early punch, Cmax may be the metric it is really leaning on.²³

What do real studies show when you compare ingredients and routes?

The easiest way to understand bioavailability is to compare molecules that behave very differently after swallowing.

Caffeine is the friendly example. In healthy adult male volunteers, Blanchard and Sawers found that orally administered caffeine was absorbed rapidly, with a mean peak time of about 29.8 minutes, and showed essentially complete absolute bioavailability at 108.3%.⁴ That does not mean every caffeine format feels the same. It means swallowed caffeine already gets into the system efficiently, so dosage-form differences are more likely to show up as onset timing, convenience, or user experience than as a dramatic gain in total exposure.

Melatonin is the opposite kind of lesson. DeMuro and colleagues found that 2 mg and 4 mg oral melatonin tablets both showed absolute bioavailability of only about 15% in healthy volunteers.⁵ That is a very different pharmacokinetic profile from caffeine. It tells you that the same word, bioavailability, can describe almost complete exposure for one active and heavy pre-systemic loss for another.

The 2023 melatonin crossover study by Ait Abdellah and colleagues is useful because it separates amount from timing. The immediate-release sublingual spray produced a Cmax of 2332 +/- 950 pg/mL and a Tmax of 23.3 +/- 6.5 minutes, while the prolonged-release oral tablet produced a Cmax of 1151 +/- 565 pg/mL and a Tmax of 64.2 +/- 44.2 minutes.⁶ The plasma melatonin to 6-sulfatoxymelatonin ratio also favored the sublingual form, which is consistent with less immediate hepatic transformation for the absorbed fraction.⁶ That is not proof that every oral mucosal product is superior. It is proof that route can change both peak and timing when the active is route-sensitive.

The oral mucosa review by Hearnden and colleagues explains why that route difference can exist. The oral mucosa is accessible, well vascularized, and attractive for local or systemic delivery partly because it can bypass hepatic first-pass metabolism for the absorbed fraction.⁷ That is the route logic behind strips, buccal films, and sublingual dosage forms. It is also why I keep emphasizing the phrase "for the absorbed fraction." A strip does not make the laws of pharmacokinetics disappear. Some of the dose is still swallowed, some molecules still permeate poorly, and some dose loads are simply too large for the route to make sense.⁷

The earlier MIHIYO pieces on how fast caffeine strips work, the first-pass effect in supplements, and supplement onset time are really parts of the same conversation. One asks how much gets into blood. Another asks what gets lost. Another asks when the peak arrives. Labels often compress all three into one claim. The science does not.

What this means for MIHIYO products

For MIHIYO products, I use bioavailability as a design filter, not a slogan. A strip is most defensible when the active is low dose, timing-sensitive, and plausible for oral mucosal delivery. That is why route logic matters more to me for products like Sleep-Support than it would for a bulky, gram-level ingredient that is going to be swallowed in practice anyway.

The same logic shapes how I think about Energy-Focus. Swallowed caffeine already has excellent absolute bioavailability.⁴ So the better formulation question is not "Can I make caffeine magically more bioavailable?" It is "Can I improve the early exposure curve, the convenience of water-free use, and the consistency of a low unit dose without pretending I changed the chemistry of caffeine itself?" That is a more honest product-design question, and it leads to more honest claims.

I also think the label conversation should keep a hard boundary between ingredient studies, route studies, and finished-product claims. The papers in this article are on molecules and dosage forms studied in research settings, not on finished MIHIYO retail products.⁴⁵⁶⁷ I am comfortable using them to explain the pharmacology. I am not comfortable pretending they prove a direct clinical outcome for a commercial supplement they never tested.

Where this word gets abused

The first abuse is treating bioavailability as if it automatically means better. Sometimes higher or faster exposure is exactly the point. Sometimes it is irrelevant. Sometimes it is undesirable. A sharper peak is not automatically a better experience if the goal is smooth exposure, lower jitter, or a more conservative dose curve.³

The second abuse is ignoring the difference between absolute and relative data. Absolute bioavailability is the clean answer to the literal question of how much of the dose reached systemic circulation. Relative bioavailability only tells you how one non-intravenous format compared with another.² If a label is using a relative formulation study to imply absolute superiority, the buyer should read that carefully.

The third abuse is skipping the route limits. Oral mucosal delivery has real advantages, but it also has real constraints: contact time, saliva washout, permeability limits, and dose-size ceilings.⁷ If the active is too bulky, too hydrophilic, or simply too high-dose, the route advantage can narrow quickly. That is why I do not think every supplement should be forced into a strip story.

The fourth abuse is forgetting that a label claim is not the same thing as a finished-product study. Excipients, adhesion, dissolution, and user technique can all change the real-world curve.

The bottom line

What is bioavailability in supplements? It is the fraction of a dose that reaches systemic circulation unchanged, but the label only becomes useful when you know which pharmacokinetic question it is answering.¹² AUC speaks to total exposure. Cmax speaks to peak level. Tmax speaks to timing.²³ Human data show how different the same word can look across ingredients: oral caffeine was essentially completely bioavailable, while oral melatonin was only about 15%, and a sublingual melatonin spray changed both peak and timing versus an oral tablet.⁴⁵⁶ My formulation view is simple: use a route advantage when route is the bottleneck. If that is not the problem, "bioavailability" is probably being used too loosely.

References

1. Kwan KC. Oral bioavailability and first-pass effects. Drug Metab Dispos. 1997;25(12):1329-1336. PMID: 9394021. <https://pubmed.ncbi.nlm.nih.gov/9394021/>
2. Toutain PL, Bousquet-Melou A. Bioavailability and its assessment. J Vet Pharmacol Ther. 2004;27(6):455-466. PMID: 15601440 / DOI: 10.1111/j.1365-2885.2004.00604.x. <https://pubmed.ncbi.nlm.nih.gov/15601440/>
3. Chen ML, Lesko L, Williams RL. Measures of exposure versus measures of rate and extent of absorption. Clin Pharmacokinet. 2001;40(8):565-572. PMID: 11523723 / DOI: 10.2165/00003088-200140080-00001. <https://pubmed.ncbi.nlm.nih.gov/11523723/>
4. Blanchard J, Sawers SJ. The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol. 1983;24(1):93-98. PMID: 6832208 / DOI: 10.1007/BF00613933. <https://pubmed.ncbi.nlm.nih.gov/6832208/>
5. DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino JS Jr. The absolute bioavailability of oral melatonin. J Clin Pharmacol. 2000;40(7):781-784. PMID: 10883420 / DOI: 10.1177/00912700022009422. <https://pubmed.ncbi.nlm.nih.gov/10883420/>
6. Ait Abdellah S, Raverot V, Gal C, Guinobert I, Bardot V, Blondeau C, Claustrat B. Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers. Drugs R D. 2023;23(3):219-229. PMID: 37438493 / DOI: 10.1007/s40268-023-00431-9. <https://pubmed.ncbi.nlm.nih.gov/37438493/>
7. Hearnden V, Sankar V, Hull K, Juras DV, Greenberg M, Kerr AR, Lockhart PB, Patton LL. New developments and opportunities in oral mucosal drug delivery for local and systemic disease. Adv Drug Deliv Rev. 2012;64(1):16-28. PMID: 21371513 / DOI: 10.1016/j.addr.2011.02.008. <https://pubmed.ncbi.nlm.nih.gov/21371513/>

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs. Focused on the R&D of high-bioavailability, fast-absorption oral dissolving strips.